NASDAQ:IMAB
I-Mab
- Stock
locale
Chinamarket
STOCKSindustry
Biotechnologywebsite
www.i-mabbiopharma.comipo date
Jan 17, 2020
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growt...Show More
Earnings
Earnings Release in 19 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus